期刊文献+

八味抗纤方治疗慢性乙型肝炎肝纤维化的临床研究 被引量:15

下载PDF
导出
摘要 目的观察八味抗纤方对慢性乙型肝炎血清肝纤维化指标、肝组织的影响。方法将66例中医辨证为气虚血瘀,湿热未尽的慢性乙型肝炎患者按2:1比例随机分为中药治疗组和对照组,两组患者均给予维生素C、复合维生素B口服,中药治疗组加用八味抗纤方,疗程6个月。观察两组患者肝功能、血清透明质酸、Ⅲ型前胶原肽、Ⅳ型胶原、层黏连蛋白等变化,18例患者行治疗前后肝组织活检。结果中药治疗组血清肝纤维化指标的联合评价效果显著优于对照组(P=0.020),中药尤其可以明显改善患者血清透明质酸的异常升高。治疗前后的肝活检比较显示,对照组肝纤维化没有自发缓解,43%(3/7例)患者病变处于进展之中。而八味抗纤方能够使73%(8/11例)患者的肝组织学病变维持稳定,18%(2/11例)患者肝纤维化得到逆转,仅9%(1/11例)患者纤维化仍在进展。结论中药八味抗纤方能有效改善血清肝纤维化指标,治疗前后肝活检病理组织学变化显示能阻止肝纤维化的进展。
出处 《北京中医药》 2010年第7期487-489,共3页 Beijing Journal of Traditional Chinese Medicine
基金 北京中医药科技发展基金资助(JJ2005-19)
  • 相关文献

参考文献6

  • 1中华医学会传染病与,寄生虫病学分会,肝病学分会.病毒性肝炎防治方案[J].中华肝脏病杂志,2000,8(6):324-329. 被引量:14010
  • 2中华中医药学会内科分会.病毒性肝炎中医辨证标准[S].中华中医药学会第11届肝胆病学术会议论文集,2004,5:188-190.
  • 3Patel K,Lajoie A,Heaton S,Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C[J].Gastroenterol Hepatol,2003,18:253-257.
  • 4王宪波,刘平,唐志鹏,陆雄,刘成海,胡义扬,徐列明,顾宏图,刘成.肝窦毛细血管化的形成机制研究[J].中华消化杂志,2004,24(5):289-292. 被引量:19
  • 5王宝恩,贾继东,张文胜.肝纤维化无创诊断模型的研究进展[J].中国中西医结合杂志,2006,26(1):5-7. 被引量:12
  • 6Dienstag J.The role of liver biopsy in chronic hepatitis C[J].Hepatology,2002,36:S152-S160.

二级参考文献24

  • 1Dienstag J.The role of liver biopsy in chronic hepatitis C.Hepatology 2002 ;36:S152-160.
  • 2Bedossa P,Dargere D,Paradis V.Sampling variability of liver fibrosis in chronic hepatitis C.Hepatology 2003 ;38:1449-1457.
  • 3Bonacini M,Hadi G,Govindarajan S,et al.Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection.Am J Gastroenterol 1997; 92:1302-1304.
  • 4Giannini E,Ceppa P,Botta F,et al.Steatosis and bile duct damage in chronic hepatitis C:distribution and relationships in a group of Northern Italian patients.Liver 1999; 19:432-437.
  • 5Imbert-Bismut F,Ratziu V,Pieroni L,et al.Biochemical markers of liver fibrosis in patients with hepatitis C virus infection:a prospective study.Lancet 2001 ;357:1069-1075.
  • 6Patel J,Gordon SC,Oh E,et al.A non-invasive panel of serum fibrosis markers can reliably differentiate hepatitis C patients with minimal fibrosis from those with fibrosis stages F2F4[abstract 770].In:The 53rd Annual Meeting of the American Association for the Study of Liver Diseases.Boston,2002.
  • 7Thierry P,Francoise IB,Mona M,et al.Overview of the di agnostic value of biochemical markers of liver fibrosis (FibroTest,HCV FibroSure) and necrosis (Acti Test) in patients with chronic hepatitis C.Comp Hepatol 2004;3:8.
  • 8Forns X,Ampurdanes S,Lovet JM,et al.Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model.Hepatology 2002; 36:986-992.
  • 9Patel K,Muir AJ,McHutchison JG.Validation of a simple predictive model for the identification of mild hepatic fibrosis in chronic hepatitis C patients.Hepatology 2003;37:1222.
  • 10Wai CT,Greenson JK,Fontana RJ,et al.A simple non-invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.Hepatology 2003; 38:518-526.

共引文献14039

同被引文献195

引证文献15

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部